Bedrijfsoverzicht
BioVie Inc. is a clinical-stage biopharmaceutical entity focused on the development of therapeutic interventions for neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company operates within the broader Healthcare sector and the specific Biotechnology industry, a domain characterized by high research and development expenditures and regulatory complexity before products reach commercialization. As of the latest available data, the enterprise carries a market capitalization of $10.18M and employs 13 individuals, reflecting a lean operational structure typical of early-stage biotech firms. The combination of a market cap under $100 million and an absence of reported annual revenue in the TTM period indicates that the company is currently in a capital-intensive development phase where valuation is driven by pipeline potential rather than current commercial performance or cash generation.
Financiële gezondheid
The company reports net income of $-17,478,136 and EBITDA of $-17,968,812 over the trailing twelve months, with no reported revenue to provide a denominator for profitability analysis. The substantial negative gap between the minimal revenue figure and the significant net loss reveals a cost structure dominated by research and development expenses and operating overheads required to advance drug candidates through clinical trials. Free cash flow stands at $-8,277,755, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating liquidity from sales. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which mathematically reflects the absence of revenue and confirms that the company has not yet achieved commercial sales to establish a profit base. The balance sheet holds $20.54M in cash against $314,915 in debt, resulting in a debt-to-equity ratio of 1.64, a configuration that suggests a leveraged position relative to equity but provides significant liquidity runway. The current ratio is 7.25, a figure that indicates robust short-term liquidity, as the company possesses ample current assets to cover its short-term liabilities despite the lack of commercial revenue. Return on Equity is -80.7% and Return on Assets is -47.2%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the asset base due to the pre-revenue nature of the business model.
Waarderingsbeoordeling
The P/E Ratio (TTM) is listed as N/A due to the net loss, while the Forward P/E is reported as -0.31, a metric that is not conventionally meaningful for a loss-making company but highlights the lack of expected near-term earnings. The Price to Book ratio is 0.53, suggesting that the market values the company's equity at a discount to its book value, which can occur when assets are valued at historical cost rather than market value or when the company lacks significant tangible assets relative to its intangible pipeline value. The Price to Sales ratio is N/A because there is no revenue, and the EV/EBITDA stands at 0.56, an alternative valuation metric that is distorted by the negative EBITDA and does not provide a standard comparable multiple for peers. The stock's 52-week high is $13.20 and the 52-week low is $1.06, defining the trading range within which the current market price fluctuates based on investor sentiment regarding the clinical pipeline. The Beta is 0.56, indicating that the stock price exhibits lower volatility relative to the broader market, moving less than half as much as the market index on average during periods of market fluctuation.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A due to the lack of historical revenue data and current profitability, preventing a calculation of growth rates or a comparison of earnings trajectory relative to sales. The company does not pay a dividend, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available earnings and cash flow are retained for reinvestment into research and development rather than distributed to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential for future commercialization of its drug therapies rather than current income generation or historical growth metrics. The financial data confirms that BioVie Inc. functions as a pure-play biotech investment reliant on future milestones rather than current cash flow or dividend income.